Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems presented retrospective data at ESMO Breast Cancer 2026 showing a 60% hepatic partial response rate for its CHEMOSAT system in liver-dominant metastatic breast cancer. The analysis of 15 heavily pre-treated patients demonstrated a median overall survival of 6.0 months, validating the liver-directed approach.
Key figures
- Drug Name
- HEPZATO KIT (melphalan)
- Phase Of Trial
- Phase 2
- Patient population N
- 15
- Hepatic partial response rate
- 60%
- Median overall survival months
- 6
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.